When federal regulators last week approved Digene Corp.'s cervical cancer test as a primary screening tool for women over 30, they catapulted what had been a follow-up test into direct competition ...

Digene Corp., a maker of medical diagnostic tests, expects the marketing potential of its DNA-based cervical cancer test to increase 10-fold if the U.S. Food and Drug Administration approves expanded ...

Digene Corp. said yesterday that the Food and Drug Administration has informed the company it won’t approve expanded use of Digene’s cervical cancer test without additional information. The FDA’s ...

Gaithersburg-based Digene, which markets a DNA-based test for cervical cancer, got a boost from the American Cancer Society's new guidelines for women and cancer screening. While the revised ...

Digene Corp. will develop a cervical cancer test designed for use in the developing world, where the largely preventable disease kills about 200,000 women a year, the Gaithersburg biotechnology ...

A recent study conducted by the department of obstetrics and gynaecology of Shrimati Kashibai Navale Medical College and AyuGen Biosciences showed the importance of cervical cancer testing using ...

Marissa Jaret Winokur‘s journey to motherhood is not typical and she wants to make sure that yours doesn’t go the same way. In 2000, at the age of 27, just as her Broadway career was starting to ...

Qiagen NV, a Dutch maker of tools for gene research, said the $1.6 billion purchase of Digene Corp. will enable it to enter the market for cancer tests. Qiagen Sunday agreed to buy Gaithersburg-based ...

A year after settling a patent dispute with a Midwest competitor, Digene has slapped that company with a lawsuit claiming it infringes on its patent for its key product. Digene says Madison, ...

Shares of Digene Corp. surged last week after a German study supported the use of the Gaithersburg biotechnology company’s screening test for cervical cancer. Digene stock closed at $23.60 Friday on ...

Shares of Digene, a maker of DNA and RNA tests, sizzled on Monday after it announced that Netherlands-based Qiagen would purchase the company in a $1.6 billion deal. Digene is best known for a test to ...